A retrospective study of DA-EPOCH with or without rituximab therapy for aggressive lymphoma

A retrospective study of DA-EPOCH with or without rituximab therapy for aggressive lymphoma - COPEARL5

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000025698

Enrollment

Registered

2017-01-17

Start date

2016-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant Lymphoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients treated with DA-EPOCH with or without rituximab therapy as first or second line therapy 2) Aggressive B-cell lymphoma (primary or relapsed/refractory) including hisitologic transformation of indolent B-cell lymphoma 3) Peripheral T-cell lymphoma (diagnosed by WHO classification 2008) 4) Permission from each institute such as IRB 5) Patients over the age of 16 years 6) DA-EPOCH(R) therapy was done between January 1, 2007 and December 31, 2015

Exclusion criteria

Exclusion criteria: Primary CNS lymphoma

Design outcomes

Primary

Measure	Time frame
4-year overall survival	—

Secondary

Measure	Time frame
Safety (Incidence of hematological toxicities, non-hematological toxicities including febrile neutropenia and etc.)	—

Countries

Japan

Contacts

Public ContactMayumi Tomita

Shimane University Shimane University Hospital innovative cancer center

tomita-m@med.shimane-u.ac.jp0853-20-2308

Outcome results